Welcome to our dedicated page for Cryoport news (Ticker: CYRX), a resource for investors and traders seeking the latest updates and insights on Cryoport stock.
Cryoport Inc (NASDAQ: CYRX) provides mission-critical temperature-controlled logistics solutions for the life sciences industry, specializing in cell/gene therapies and biologics transport. This page serves as the definitive source for verified corporate announcements, financial updates, and operational developments.
Investors and industry professionals will find timely updates on earnings reports, strategic partnerships, technology innovations, and regulatory milestones. All content is curated to support informed decision-making while adhering to financial disclosure standards.
The repository includes press releases covering logistics network expansions, new cryogenic system deployments, and clinical trial support agreements. Each update reflects Cryoport's role in enabling safe biological material transport across 50+ global locations.
Bookmark this page for direct access to primary source materials about Cryoport's temperature-controlled supply chain solutions, maintained with strict neutrality and compliance with financial reporting guidelines.
Cryoport (NASDAQ: CYRX) reported Q3 2025 revenue of $44.2M, up 15% year‑over‑year, and raised full‑year continuing operations revenue guidance to $170.0–$174.0M. Commercial cell & gene therapy revenue grew 36% to $8.3M; Life Sciences Services revenue rose 16% and Life Sciences Products revenue rose 15% in Q3. Gross margin improved to 48.2% in Q3. Adjusted EBITDA from continuing operations narrowed to a $0.6M loss in Q3. Cryoport held $421.3M cash and completed share repurchases of 483,397 shares for $3.7M. The company noted strategic moves including a new Paris Global Supply Chain Center, MVE product launches, and a DHL partnership.
Cryoport (NASDAQ: CYRX) reported Q3 2025 revenue of $44.2M, up 15% year‑over‑year, and raised full‑year continuing operations revenue guidance to $170.0–$174.0M. Commercial cell & gene therapy revenue grew 36% to $8.3M; Life Sciences Services revenue rose 16% and Life Sciences Products revenue rose 15% in Q3. Gross margin improved to 48.2% in Q3. Adjusted EBITDA from continuing operations narrowed to a $0.6M loss in Q3. Cryoport held $421.3M cash and completed share repurchases of 483,397 shares for $3.7M. The company noted strategic moves including a new Paris Global Supply Chain Center, MVE product launches, and a DHL partnership.
Cryoport (NASDAQ: CYRX) announced that Cryoport Systems achieved ISO 21973:2020 certification, the international standard for transport of human cells for therapeutic use, on October 30, 2025.
The company participated in developing the standard, says the certification strengthens traceability, environmental control, and chain-of-custody safeguards for cell and gene therapies and is applied across regenerative, reproductive medicine, and animal health operations. Cryoport also cites its 2025 CPHI Award for Supply Chain Excellence and points investors to a company whitepaper and website for more details.
Cryoport (NASDAQ: CYRX) announced that Cryoport Systems achieved ISO 21973:2020 certification, the international standard for transport of human cells for therapeutic use, on October 30, 2025.
The company participated in developing the standard, says the certification strengthens traceability, environmental control, and chain-of-custody safeguards for cell and gene therapies and is applied across regenerative, reproductive medicine, and animal health operations. Cryoport also cites its 2025 CPHI Award for Supply Chain Excellence and points investors to a company whitepaper and website for more details.
Cryoport (Nasdaq: CYRX) will report third quarter 2025 financial results for the period ended September 30, 2025 on Tuesday, November 4, 2025 after U.S. markets close.
An earnings release and a document titled "Cryoport Third Quarter 2025 in Review" will be issued at 4:05 p.m. ET, followed by a management questions-and-answers conference call at 5:00 p.m. ET the same day. The review document and slide deck will be available in the Investor Relations section at https://ir.cryoportinc.com/news-events/ir-calendar.
The live call dial-in numbers are 1-800-717-1738 (U.S.) and 1-646-307-1865 (International) with conference ID 1120106. A replay will be available online ~three hours after the call and by dial-in until November 11, 2025 (replay numbers: 1-844-512-2921 U.S.; 1-412-317-6671 International).
Cryoport (Nasdaq: CYRX) will report third quarter 2025 financial results for the period ended September 30, 2025 on Tuesday, November 4, 2025 after U.S. markets close.
An earnings release and a document titled "Cryoport Third Quarter 2025 in Review" will be issued at 4:05 p.m. ET, followed by a management questions-and-answers conference call at 5:00 p.m. ET the same day. The review document and slide deck will be available in the Investor Relations section at https://ir.cryoportinc.com/news-events/ir-calendar.
The live call dial-in numbers are 1-800-717-1738 (U.S.) and 1-646-307-1865 (International) with conference ID 1120106. A replay will be available online ~three hours after the call and by dial-in until November 11, 2025 (replay numbers: 1-844-512-2921 U.S.; 1-412-317-6671 International).
MVE Biological Solutions (NASDAQ: CYRX) unveiled integrated real-time condition monitoring for its MVE SC 4/2 V and 4/3 V cryogenic dewars on Oct 7, 2025. The systems embed SmartTag (LTE, up to 120 days battery) or CryoBeacon (BLE 5.0, logs to –200°C plus ambient humidity) into dewar lids and stream data to MVECloud, an FDA 21 CFR Part 11 and GAMP 5 compliant web/mobile platform offering visibility, real-time alerts, QR-based data retrieval, and reporting.
The launch positions MVE to offer connected assets for shipments and stationary storage and to pursue services and potential subscription-based revenue as part of Cryoport's broader monitoring strategy.
MVE Biological Solutions (NASDAQ: CYRX) unveiled integrated real-time condition monitoring for its MVE SC 4/2 V and 4/3 V cryogenic dewars on Oct 7, 2025. The systems embed SmartTag (LTE, up to 120 days battery) or CryoBeacon (BLE 5.0, logs to –200°C plus ambient humidity) into dewar lids and stream data to MVECloud, an FDA 21 CFR Part 11 and GAMP 5 compliant web/mobile platform offering visibility, real-time alerts, QR-based data retrieval, and reporting.
The launch positions MVE to offer connected assets for shipments and stationary storage and to pursue services and potential subscription-based revenue as part of Cryoport's broader monitoring strategy.
Cryoport (NASDAQ: CYRX) has announced the opening of a new 55,000-square-foot Global Supply Chain Center (GSCC) in Louvres, France, near Paris Charles de Gaulle Airport. The facility represents the company's third global supply chain center campus, strengthening its temperature-controlled supply chain solutions network.
The Paris GSCC will provide 24-hour worldwide dispatch capabilities and immediate logistics support for biopharma, including cell and gene therapies, biologics, animal health, and reproductive medicine. Future phases will incorporate BioServices, biostorage, QP drug management, and Importer of Record services. The facility's development was partially funded by a grant from the Île-de-France region, with an official grand opening scheduled for November 20, 2025.
Cryoport (NASDAQ: CYRX) has announced the opening of a new 55,000-square-foot Global Supply Chain Center (GSCC) in Louvres, France, near Paris Charles de Gaulle Airport. The facility represents the company's third global supply chain center campus, strengthening its temperature-controlled supply chain solutions network.
The Paris GSCC will provide 24-hour worldwide dispatch capabilities and immediate logistics support for biopharma, including cell and gene therapies, biologics, animal health, and reproductive medicine. Future phases will incorporate BioServices, biostorage, QP drug management, and Importer of Record services. The facility's development was partially funded by a grant from the Île-de-France region, with an official grand opening scheduled for November 20, 2025.
FAQ
What is the current stock price of Cryoport (CYRX)?
What is the market cap of Cryoport (CYRX)?
